PASSAGE BIO, INC. Operating Cash Flow
PASSAGE BIO, INC. (PASG) reported Operating Cash Flow of -$22.17 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-03
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.18M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.99M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.48M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.85M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$78.26M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$118.21M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$126.88M.
- PASSAGE BIO, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$80.52M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.18M derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | -$22.17M S-4/A · filed 2026-09-03 | -$28.65M derived: sum of 3 quarters · filed 2026-09-03 | -$33.50M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | -$12.99M S-4 · filed 2026-07-21 | -$19.47M derived: sum of 2 quarters · filed 2026-09-03 | -$24.32M derived: sum of 3 quarters · filed 2026-09-03 | -$30.65M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | -$6.48M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$11.33M derived: sum of 2 quarters · filed 2026-09-03 | -$17.66M derived: sum of 3 quarters · filed 2026-09-03 | -$31.51M S-4/A · filed 2026-09-03 |
| 2025-09-30 | -$4.85M derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | -$11.18M derived: sum of 2 quarters · filed 2026-09-03 | -$25.03M 10-Q · filed 2025-11-10 | -$33.47M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | -$6.33M derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | -$20.18M S-4/A · filed 2026-09-03 | -$28.62M derived: sum of 3 quarters · filed 2026-09-03 | -$36.07M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | -$13.85M S-4 · filed 2026-07-21 | -$22.29M derived: sum of 2 quarters · filed 2026-09-03 | -$29.74M derived: sum of 3 quarters · filed 2026-09-03 | -$42.87M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | -$8.44M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$15.89M derived: sum of 2 quarters · filed 2026-09-03 | -$29.03M derived: sum of 3 quarters · filed 2026-09-03 | -$47.96M S-4/A · filed 2026-09-03 |
| 2024-09-30 | -$7.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$20.58M derived: sum of 2 quarters · filed 2025-11-10 | -$39.51M 10-Q · filed 2025-11-10 | -$59.03M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$13.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$32.06M 10-Q · filed 2025-08-12 | -$51.58M derived: sum of 3 quarters · filed 2025-08-12 | -$70.74M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$18.93M 10-Q · filed 2025-05-13 | -$38.45M derived: sum of 2 quarters · filed 2025-05-13 | -$57.61M derived: sum of 3 quarters · filed 2025-05-13 | -$74.75M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$19.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$38.68M derived: sum of 2 quarters · filed 2025-03-04 | -$55.82M derived: sum of 3 quarters · filed 2025-03-04 | -$78.26M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$19.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$36.30M derived: sum of 2 quarters · filed 2024-11-13 | -$58.75M 10-Q · filed 2024-11-13 | -$82.77M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$17.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$39.59M 10-Q · filed 2024-08-08 | -$63.61M derived: sum of 3 quarters · filed 2024-08-08 | -$87.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$22.45M 10-Q · filed 2024-05-14 | -$46.47M derived: sum of 2 quarters · filed 2024-05-14 | -$69.86M derived: sum of 3 quarters · filed 2024-05-14 | -$95.94M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$24.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$47.42M derived: sum of 2 quarters · filed 2024-03-04 | -$73.50M derived: sum of 3 quarters · filed 2024-03-04 | -$118.21M 10-K · filed 2024-03-04 |
| 2022-09-30 | -$23.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$49.48M derived: sum of 2 quarters · filed 2023-11-13 | -$94.19M 10-Q · filed 2023-11-13 | -$124.96M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$26.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$70.79M 10-Q · filed 2023-08-07 | -$101.57M derived: sum of 3 quarters · filed 2023-08-07 | -$142.63M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$44.71M 10-Q · filed 2023-05-11 | -$75.49M derived: sum of 2 quarters · filed 2023-05-11 | -$116.54M derived: sum of 3 quarters · filed 2023-05-11 | -$140.87M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$30.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$71.83M derived: sum of 2 quarters · filed 2023-03-06 | -$96.16M derived: sum of 3 quarters · filed 2023-03-06 | -$126.88M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$41.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$65.39M derived: sum of 2 quarters · filed 2022-11-10 | -$96.10M 10-Q · filed 2022-11-10 | -$125.53M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$24.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$55.05M 10-Q · filed 2022-08-04 | -$84.47M derived: sum of 3 quarters · filed 2022-08-04 | -$102.00M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$30.72M 10-Q · filed 2022-05-16 | -$60.14M derived: sum of 2 quarters · filed 2022-05-16 | -$77.67M derived: sum of 3 quarters · filed 2022-05-16 | -$89.39M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$29.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$46.95M derived: sum of 2 quarters · filed 2022-03-03 | -$58.67M derived: sum of 3 quarters · filed 2022-03-03 | -$80.52M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$17.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$29.25M derived: sum of 2 quarters · filed 2021-11-04 | -$51.10M 10-Q · filed 2021-11-04 | -$68.57M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$11.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$33.57M 10-Q · filed 2021-08-05 | -$51.04M derived: sum of 3 quarters · filed 2021-08-05 | -$62.47M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$21.85M 10-Q · filed 2021-05-05 | -$39.33M derived: sum of 2 quarters · filed 2021-05-05 | -$50.75M derived: sum of 3 quarters · filed 2021-05-05 | -$61.53M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | -$17.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$28.90M derived: sum of 2 quarters · filed 2021-03-03 | -$39.68M derived: sum of 3 quarters · filed 2021-03-03 | -$39.90M 10-K · filed 2021-03-03 |
| 2019-09-30 | -$11.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$22.20M derived: sum of 2 quarters · filed 2020-11-10 | -$22.42M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$10.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$10.99M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$214.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |